Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zinc aluminium ointment is a novel topical formulation developed by the Digestive Diseases Department at the Pontificia Universidad Católica de Chile for the treatment of faecal incontinence. The ointment contains zinc and aluminium as its primary active ingredients and is applied to the perianal region. In clinical research, specifically a randomized, double-blind, placebo-controlled trial, the ointment demonstrated significant efficacy in reducing faecal incontinence symptoms as measured by the Wexner score and improving patient quality of life via the Fecal Incontinence Quality of Life (FIQL) score. The treatment is typically applied for a period of 3 to 4 weeks and has been reported to be well-tolerated with no significant adverse effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on zinc aluminium ointment.